(PS: molly, haven't looked at TERN. Seems it's done rather well though!)
"Launch of Synbiosis ProtoCOL 3 HD
May 8th, 2018
Cambridge, UK: Synbiosis, a long-established, expert manufacturer of automated microbiological systems, is delighted to introduce the ProtoCOL 3 HD, automated colony counting and zone measurement system. The system with its sensitive new camera can generate high definition images of colonies and inhibition zones, making the ProtoCOL 3 HD ideal for vaccine and antibiotic development laboratories.
ProtoCOL 3 HD, the newest addition to the highly acclaimed ProtoCOL 3 automated colony counting and inhibition zone measurement range, features a compact light-tight cabinet, housing patented three colour LED lighting and a super-high 5-megapixel CCD camera integrated to user-friendly software. At the press of a button, this new system allows microbiologists to automatically read plates to detect colonies as small as 43µm and measure zones with an average accuracy of more than 99.9%, making the ProtoCOL 3 HD a must-have for vaccine potency and antibiotic testing laboratories wanting to optimise the accuracy of their zone and count data.
With the ProtoCOL 3 software, microbiologists can read plates of up to 150 mm diameter and optimise batch design for each plate type. The software includes as standard, an Inhibition Zone Measurement module to measure the diameter of inhibition zones for applications including Single Radial Immunodiffusion (SRD) and a Pour Plate module for counting colonies on pour, settle and spread plates. All the data generated can be easily exported into a spreadsheet (Excel/OpenOffice) or the optional UNISTAT statistics package for analysis or transferred to a LIMS. The software is 21 CFR Part 11 compliant with user access levels and a full audit trail, making ProtoCOL 3 HD suited for use in highly regulated microbiology laboratories.
For greater flexibility, microbiologists can add zone measurement modules such as eAST, for use with antibiotic susceptibility testing (AST) plates in accordance with EUCAST and CLSI guidelines and Minimum Inhibition Concentration (MIC) for reading zones around MIC strips. There are also specialised colony counting options such as the AMES test, SBA (serum bactericidal assay) and OPKA (opsonophagocytic killing assay) to cost-effectively customise the ProtoCOL 3 HD to suit any microbiology laboratorys needs....
...Our ProtoCOL systems have been successfully used by all the major global pharmaceutical and biotech companies for many years, comments Kate George, Sales & Technical Director at Synbiosis, By adding the latest in imaging and software to our new ProtoCOL 3 HD, microbiologists can generate robust, reproducible, and more critically, fully traceable results. This means our third generation ProtoCOL remains the intelligent choice for highly regulated laboratories developing vaccines and antibiotics."
Scientific Digital Imaging plc, the AIM quoted group focused on the design and manufacture of scientific and technology products for use by the life science, healthcare, astronomy, consumer manufacturing and art conservation markets, is pleased to announce the forthcoming appointment of Jon Abell as Chief Financial Officer of the Company, effective 2 July 2018.
Mr. Abell will bring over 35 years of business experience to the Board. He is currently Divisional VP of Finance, Electronic Instruments Group, at Ametek, Inc. where his principle duties include performance management, M&A, business controls and accounting for several scientific and industrial instrument businesses.
Mr. Abell started his career as a financial analyst and then management accountant for various industrial companies in the UK and Italy, before undertaking his MBA at Columbia Business School. He subsequently went on to senior financial management roles in Germany, the Netherlands, USA and UK including at Philips Electronics and Broadcom Inc.
Further information with respect to Jonathan Abell, as required by the AIM Rules, is set out below.
Ken Ford, Chairman of SDI, commented: "We are delighted that Jonathan has agreed to join SDI and are confident that his considerable experience will strengthen the Board."
"Sleek, new blue G:BOX multi-application imaging range from Syngene
May 1st, 2018
Cambridge, UK: Syngene, a world-leading manufacturer of image analysis solutions, is delighted to introduce its new look G:BOX range of upgradeable multi-application imaging systems. Designed with a sleek new darkroom, each of these systems includes top quality imaging features, making it easy for scientists to accurately quantify DNA and protein on all types of gels and blots.
The new look range (G:BOX Chemi XRQ, G:BOX Chemi XX6 and XX9) combine a unique motorized stage (XX6 and XX9) and super-cooled camera inside a streamlined new light-tight darkroom. These features ensure G:BOX systems produce true to life, low-noise optical images rather than poor quality, digitally enhanced ones. With a G:BOX system, scientists can resolve close chemi and fluorescent bands and know theyre real, which means these systems are ideal for robust quantification of as little as femtogram quantities of DNA and proteins on multiple gel and blot types.
With the option to add Red, Green, Blue and Infra Red Hi-Intensity ( HI-LED) lights that are up to 200 times brighter than standard LEDs, the new G:BOX range offers fast exposure times and produces brilliant multiplex fluorescence images. With a G:BOX Chemi system, users can detect up to five fluorescent channels sequentially (from UV to IR) on Western blots. For higher performance and resolution, researchers can use a G:BOX Chemi XX6 or XX9 for imaging close bands or spots even on complex 2D gels.
At the heart of the new look G:BOX range is the unique, application driven, GeneSys software which walks users through hassle-free imaging set up. With minimal hands on time, scientists can easily design customised workflows to rapidly and reproducibly produce publication quality images of chemi, multiplex fluorescence blots, DNA and stain-free protein gels. The software includes QuickQuant, for band quantification, saving scientists time, by allowing them to quantify images of protein and DNA bands while capturing their blot or gel images at their G:BOX system.
To complete the package, the new G:BOX systems come with Syngenes exclusive three-year service and support warranty, unlimited copies of GeneTools image analysis software and free software upgrades, ensuring scientists will always have access to the latest application capabilities without any hidden extra costs.
To find out more about the exciting new look G:BOX range, please click this link:
Modern researchers want to get optimum imaging from simple gels right through to multiplex fluorescence applications, with minimal hands on time says Dr Martin Biggs, Sales Manager at Syngene. Our new systems perform perfectly to fit these needs, so scientists wanting hassle free imaging and results they can trust, should look at Syngenes new G:BOX range today.
"The division, which is the UK's largest independent manufacturer of electrochemical sensors for water based applications, delivered a stronger second half performance than was previously expected which in turn was assisted by increased demand from two large OEM customers. Additionally, Sentek has taken up the opportunity to facilitate continued growth with an added extra facility to double capacity that had previously been earmarked being adjacent to its existing HQ."
"Creedon, while content with the progress, anticipates further additions to the group with a sizeable banking facility now in place to support that goal should they need it. There is he says, currently a strong pipeline of further potential acquisitions that fit the bill for SDI and holders or watchers of the shares will no doubt hear more on that front in due course."
"sales have been made overseas in both Norway and Romania which sees the total since launch of the device now standing at 76. The vast US market also remains on the agenda for future adoption and growth, although it would appear that the UK, given that looming deadline date remains the primary focus for now."
"Creedon is certainly not one to raise hopes on the device, but says he will be interested to see exactly what happens come July, as this is the date that has been set by the department of health (DoH) regarding healthcare providers engaged in the management and decontamination of surgical instruments implementing their guidance on protein levels being measured directly on the surface of the instrument."
Scientific Digital Imaging plc, the AIM quoted group focused on the design and manufacture of scientific and technology products for use by the life science, healthcare, astronomy, consumer manufacturing and art conservation markets, is pleased to announce an update on trading for the year ending 30 April 2018.
The Group now expects full year revenues, adjusted* and reported profit before tax to be moderately ahead of previous expectations. In addition, adjusted* and reported profit after tax is expected to benefit from a reduced Group tax charge which includes increased R&D tax credits accrued for both FY18 and FY17.
The Group expects to report significant revenue growth against FY17, reflecting both organic growth, and the acquisition of Astles Control Systems in H2 FY17, Applied Thermal Control in H1 FY18, and a contribution from the smaller Quantum Scientific Imaging acquisition in H2 FY18. Sentek's single-use electrodes and Atik Camera's new products for astronomy and life science applications have been key to delivering the organic sales growth.
Group gross margin is expected to be ahead of FY17 mainly due to the inclusion of a one-off retrospective licencing payment for the sale of Auto-Montage imaging software in Synoptics' H1 FY18 sales, as previously disclosed in the interim results.
Ken Ford, Chairman of SDI, commented:
"SDI is benefitting from its acquisitions as well as from the improvements management continue to make across the whole Group. We look forward to further growth in the new financial year."
The final results for the year ended 30 April 2018 will be released in July 2018.
* before amortisation of acquired intangibles, share based payments and acquisition and reorganisation costs
"Universal-Investment-Luxembourg S.A. is a wholly owned subsidiary of Universal-Investment-Gesellschaft mbH, Frankfurt am Main. With more than 130 billion in funds under management (December 2011), more than 1000 special investor and mutual fund mandates and around 400 employees at both locations, the group is one of Germanys biggest and most successful investment companies."
ProReveal Testimonial - Nottingham University Hospitals NHS Trust
We purchased a ProReveal in May 2017 because we needed a user-friendly in-situ protein detection method to comply with the new Department of Health regulations on testing reprocessed surgical instruments. Since using the ProReveal, we have identified areas for improvement in our processes and instruments that we cant clean. This has helped us to get our decontamination process to routinely clean to less than 5 micrograms of residual protein per instrument side, which were very pleased with.
The ProReveal is great technology and is easy to use as it guides us step by step. In fact, we like it so much that we often show the ProReveal to visitors to our department. The best thing about having a ProReveal is that we dont have to rely on subjective judgement calls if there are process issues because we have traceable, quantitative data to assure us that the surgical instruments were sending back to be used on patients are safe and fit for purpose.
Alison Gee, Sterile Services and Stores Manager, Nottingham University Hospitals NHS Trust, Nottingham, UK."
Nottingham University Hospitals Trust NHS Trust adopts ProReveal system
Cambridge, UK: Synoptics Health, a manufacturer of innovative digital imaging systems for healthcare applications, today announced that its ProReveal test to accurately detect proteins on surgical instruments is being used at Nottingham University Hospitals NHS Trust, one of the UKs largest NHS run Sterile Services Departments (SSDs). ProReveal is being used to check the washer-disinfection process maintains its excellent cleaning standards and is helping to prevent patients at this hospital trust from accidentally contracting infections such as vCJD (Creutzfeldt Jakob Disease) from protein contaminated surgical instruments.
The SSD at Nottingham University Hospitals NHS Trust is one of the first in the UK to adopt the highly sensitive ProReveal in-situ fluorescence test to quantify how much protein remains on surgical instruments after they have been decontaminated. SSD personnel at the hospital test how well their washer-disinfection equipment has performed using the ProReveal (the only commercial in-situ protein detection test currently available that complies with new UK Department of Health [DoH] guidelines) to directly measure proteins on instrument surfaces which cannot be detected by eye or with a swab test. This is making checking the efficacy of the decontamination process more accurate.
Alison Gee, Sterile Services and Stores Manager at Nottingham University Hospitals NHS Trust explained: The Department of Health guidance has changed and SSDs are expected to move to in situ testing for residual protein on surgical instruments. This is particularly important for instruments which are likely to have been in contact with tissue potentially harbouring prions that could cause infections such as vCJD. This change in regulations has actually allowed us to more easily access the funding to purchase and install a ProReveal in our department.
Alison continued: Since using ProReveal in the past year, we have had very good results, but we have found that a few instruments sometimes have slightly more than the target of five micrograms of protein on them, due to factors such as positioning in the washer-disinfector. We have also identified one type of instrument that we cannot clean adequately for re-use which is therefore being replaced. Neither of these problems were identified using swab testing. This has prompted us to re-train our staff on how to load our machines correctly and to contact the instrument manufacturer to discuss decontamination processes for their products. Additionally, when we had an issue with our water softener, we used the ProReveal and it assured us that the water quality had not affected the decontamination process and the surgical instruments were safe to use. This meant we didnt have to do routine manual pre-cleaning on everything, so we avoided having an operational backlog and cancelling patients surgery. We are very pleased to have the ProReveal as it is assuring us that the surgical instruments we are returning to be used on patients are safe and fit for purpose.
Guy Fiddian, of Synoptics Health concluded: Were delighted that one of the UKs largest NHS Sterile Services Departments is implementing the ProReveal as part of its modern approach to quality control of its decontamination process. Nottingham is one of the first NHS trusts in England to install a ProReveal and its SSD staffs willingness to embrace using in-situ testing of reprocessed surgical instruments is a great testament to the fact that this excellent trusts ethos of 'working together to be the best for patients' is at the heart of its care.
Any thoughts? Looking at the institutional shareholdings, could be a sell down of one of the bigger ones or a complete sell off by one of the medium ones at around 3m shares. Anything to add, Gretel especially, since I know you watch these carefully?
Peskett Solutions devoted their entire stand at a recent exhibition to ProReveal (I seem to remember ProReveal is now in 15 NHS trusts compared to the 10 quoted here as per the Cambridge News article?):
"Quick, in-situ test for residual protein on reprocessed instruments
23rd January 2018
Delegates visiting Peskett Solutions stand at IDSc were keen to learn about ProReveal, currently the only protein detection test that is fully compliant with the requirements of the updated HTM01-01.
This year we devoted our stand to the ProReveal protein detection system, explains Matthew Peskett, pictured right. The quick, sensitive, in-situ test to detect residual proteins using fluorescence makes it easy to check the cleanliness of reprocessed instruments. Ten NHS trusts are already benefiting from the adoption of the system.
For further information or to arrange a demonstration, call Peskett Solutions on 01323 511038"
Good to see the non-exec buying shares yesterday at 31.46p. And also reassuring to see him today being issued options only exercisable at 33p. For them to be materially profitable after tax the share price will have to be 50p+ for starters, and hopefully a lot more:
Important message from the Financial Conduct Authority:
Posting inside information that is not public knowledge, or information that is false or misleading, may constitute market abuse.
This could lead to an unlimited fine and up to seven years in prison.
If you have any information, concerns or queries about market abuse, click here.
The content of the messages posted represents the opinions of the author, and does not represent the opinions of Interactive Investor Trading Limited or its affiliates and has not been approved or issued by Interactive Investor Trading Limited.
You should be aware that the other participants of the above discussion group are strangers to you and may make statements which may be misleading, deceptive or wrong.
Please remember that the value of investments or income from them may go down as well as up and that the past performance of an investment is not a guide to its performance in the future.
The discussion boards on this site are intended to be an information sharing forum and is not intended to address your particular requirements.
Whilst information provided on them can help with your investment research you need to consider carefully whether you should make (or refraining from making) investment or other decisions based on what you see without doing further research on investments you are interested in.
Participating in this forum cannot be a substitute for obtaining advice from an appropriate expert independent adviser who takes into account your circumstances and specific investment needs in selected investments that are appropriate for you.